Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry - Takeaways - MDSpire

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

  • By

  • Amy S. Paller

  • Danielle Marcoux

  • Michele Ramien

  • Eulalia Baselga

  • Vania Oliveira de Carvalho

  • Ledit R. F. Ardusso

  • Marlies de Graaf

  • Suzanne Pasmans

  • Mirna Toledo-Bahena

  • Cory J. Rubin

  • Joel C. Joyce

  • Lara Wine Lee

  • Rajan Gupta

  • Bryan Adams

  • Marius Ardeleanu

  • Annie Zhang

  • April 17, 2026

  • 0 min

Share

  • 1

    The PEDISTAD Registry provides real-world data on systemic therapies for moderate-to-severe atopic dermatitis in children aged 12 and younger.

  • 2

    Findings indicate that systemic treatments can significantly improve symptoms and quality of life in pediatric patients.

  • 3

    The study highlights the importance of personalized treatment plans based on individual patient needs and responses.

  • 4

    Adverse effects of systemic therapies were monitored, emphasizing the need for careful management in young patients.

  • 5

    Overall, the research underscores the effectiveness of systemic therapies in managing atopic dermatitis in children.

Original Source(s)

Related Content